Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ocrelizumab, and Interferon beta-1a

被引：0
|
作者：
Hersh, Carrie [1 ]
Aladro-Benito, Yolanda [2 ]
Lewin, James B. [3 ]
Shen, Changyu [3 ]
Bozin, Ivan [4 ]
Sun, Zhaonan [3 ]
机构：
[1] Cleveland Clin, Clin Lou Ruvo Ctr Brain Hlth Las Vegas, Las Vegas, NV USA
[2] Hosp Univ Getafe, Madrid, Spain
[3] Biogen, Cambridge, MA USA
[4] Biogen, Baar, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P831/1806
引用
收藏
页码：641 / 641
页数：1
相关论文
共 50 条
  • [21] Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research
    Signorovitch, James E.
    Sikirica, Vanja
    Erder, M. Haim
    Xie, Jipan
    Lu, Mei
    Hodgkins, Paul S.
    Betts, Keith A.
    Wu, Eric Q.
    VALUE IN HEALTH, 2012, 15 (06) : 940 - 947
  • [22] POPULATION-ADJUSTED TREATMENT COMPARISONS: ESTIMATES BASED ON MAIC (MATCHING-ADJUSTED INDIRECT COMPARISONS) AND STC (SIMULATED TREATMENT COMPARISONS)
    Phillippo, D. M.
    Ades, A.
    Dias, S.
    Palmer, S.
    Abrams, K. R.
    Welton, N. J.
    VALUE IN HEALTH, 2017, 20 (05) : A339 - A339
  • [23] Geometric approaches to assessing the numerical feasibility for conducting matching-adjusted indirect comparisons
    Glimm, Ekkehard
    Yau, Lillian
    PHARMACEUTICAL STATISTICS, 2022, 21 (05) : 974 - 987
  • [24] REVIEW OF NICE HTA SUBMISSIONS INCLUDING MATCHING-ADJUSTED INDIRECT COMPARISONS AND SIMULATED TREATMENT COMPARISONS
    Muresan, B.
    Hu, Y.
    Postma, M. J.
    Ouwens, M. J.
    Heeg, B.
    VALUE IN HEALTH, 2018, 21 : S24 - S24
  • [25] Synthesis of Matching-Adjusted Indirect Comparisons of Ozanimod for Relapsing Remitting Multiple Sclerosis
    Paul, D.
    Swallow, E.
    Patterson-Lomba, O.
    Branchcomb, T.
    Gomez-Lievano, A.
    Liu, J.
    Dua, A.
    McGinley, M.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 47 - 47
  • [26] Comparative effectiveness of ozanimod versus dimethyl fumarate: results of a matching-adjusted indirect comparison
    Cohan, S.
    Kumar, J.
    Arndorfer, S.
    Zhu, X.
    Zivkovic, M.
    Tencer, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 140 - 140
  • [27] Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
    Hauser, S. L.
    Bar-Or, A.
    Comi, G.
    Giovannoni, G.
    Hartung, H. -P.
    Hemmer, B.
    Lublin, F.
    Montalban, X.
    Rammohan, K. W.
    Selmaj, K.
    Traboulsee, A.
    Wolinsky, J. S.
    Arnold, D. L.
    Klingelschmitt, G.
    Masterman, D.
    Fontoura, P.
    Belachew, S.
    Chin, P.
    Mairon, N.
    Garren, H.
    Kappos, L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03): : 221 - 234
  • [28] Matching-adjusted indirect comparisons of ixekizumab and secukinumab using etanercept and ustekinumab bridge comparators
    Wu, J. J.
    Saure, D.
    Schacht, A.
    Mallbris, L.
    Wilhelm, S.
    Dossenbach, M.
    Burkhardt, N.
    Nast, A.
    Warren, R. B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 44 - 44
  • [29] ANALYSIS OF FACTORS INFLUENCING ACCEPTANCE OF DATA FROM MATCHING-ADJUSTED INDIRECT COMPARISONS BY NICE
    Lach, K.
    Smith, N.
    VALUE IN HEALTH, 2020, 23 : S3 - S3
  • [30] Matching-adjusted indirect comparisons of Ixekizumab and Secukinumab using Etanercept and Ustekinumab Bridge Comparators
    Wu, J.
    Saure, D.
    Schacht, A.
    Mallbris, L.
    Wilhelm, S.
    Dossenbach, M.
    Nast, A.
    Warren, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S58 - S58
12345